Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crimson 1
2020-000996-19Phase 3
- Sponsor
- Gyre Therapeutics
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, single-arm trial of marzeptacog alfa (activated) in hemophilia A and hemophilia B (HB), sponsored by Gyre Therapeutics. Primary endpoint: Effective hemostasis at 24 hours.
02
Drugs
marzeptacog alfa (activated)
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2020-000996-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000996-19.